タナカ ジユンジ   TANAKA Junji
  田中 淳司
   所属   医学部 医学科(東京女子医科大学病院)
   職種   教授・基幹分野長
論文種別 総説
言語種別 英語
査読の有無 査読あり
表題 Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies.
掲載誌名 正式名:Hematological oncology
略  称:Hematol Oncol
ISSNコード:10991069/02780232
掲載区分国外
巻・号・頁 39(1),pp.11-19
著者・共著者 Tanaka Junji†*
担当区分 筆頭著者,責任著者
発行年月 2021/02
概要 Natural killer (NK) cells have a potent cytotoxic activity against leukemia and lymphoma without recognition of human leukocyte antigen (HLA) molecules. Chimeric antigen receptor-engineered NK cells (CAR-NK cells) can be produced from the NK92 cell line, peripheral blood, cord blood, and induced pluripotent stem cells for immunotherapy of malignant tumor cells. Recently, the safety and efficacy of HLA-mismatched allogeneic cord blood-derived CD19 CAR-NK cell therapy for CD19-positive hematological malignancies have been reported. However, the durability of clinical effects has not been clarified. The characteristics of CAR-NK cells with a strong antileukemia/lymphoma effect and better proliferative capacity without severe adverse effects may be promising for overcoming intractable hematological malignancies as an off-the-shelf allogeneic cellular therapy.
DOI 10.1002/hon.2802
PMID 32905618